Prof. Dr. Bernd Bodenmiller
Bernd Bodenmiller is the Founding Director of the DQBM and holds UZH's Professorial Chair for Quantitative Biology. The Bodenmiller lab focuses on systems precision oncology and develops novel experimental and computational approaches for the comprehensive spatial analysis of healthy and diseased tissues. The resulting data is used to model tumours as multicellular regulatory circuits to guide precision treatment decisions. The ultimate goal is to provide “plug and play” diagnostic platforms that can be readily used in the clinics to support the work of oncologists. Bernd Bodenmiller is recipient of ERC Starting and Consolidator grants and an IMI2 Human Tumour Microenvironment Immunoprofiling Grant.
Prof. Dr. med. Michael Krauthammer
Michael Krauthammer is DQBM's Vice-Director and holds UZH's Professorial Chair for Medical Informatics. The Krauthammer lab is working on clinical data science and translational bioinformatics. They aim to i) deploy smart analytics for improving health care processes for patients, physicians and other professionals, and ii) perform knowledge discovery from large biomedical data sets und developing data-driven solution for disease prevention, diagnosis and management.
Prof. Dr. Rolf Kümmerli
Rolf Kümmerli holds UZH's professorial Chair for Evolutionary Microbiology. The Kümmerli lab combines top-down next-generation sequencing technologies and bottom-up approaches in microbiology to understand how bacterial communities can be manipulated to i) maintain beneficial host functions, ii) steer polymicrobial infections towards lower virulence; or iii) interfere with the pathogen’s cooperative network, with the ultimate goal of developing novel therapeutic approaches for patients that disarm pathogens, prevent resistance evolution, and successfully treat infections. Rolf Kümmerli is recipient of an ERC Consolidator grant.
Prof. Dr. Magdalini Polymenidou
Magdalini Polymenidou holds UZH's Professorial Chair for Biomedicine, in particular Molecular Pathogenesis of Neurodegeneration. The Polymenidou lab is working on two heterogeneous and fatal neurodegenerative diseases: amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). They use mouse models and human long-lived neuronal models to understand the molecular mechanisms that drive the initiation and progression of ALS and FTD. Their aim is to gain deep mechanistic understanding of ALS and FTD to inspire rational design of target-based therapies for these devastating diseases.